,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04', 'bcsm', 'breast']
#asco22 trendy: her-2 ihc 1+ and 2+ immunohistochemistry path report in breast cancer is now oldie but goldie. #bcsm destiny-04 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm